Duty-Free Expansion and Retail Resilience Highlight Hong Kong's Sector Divergence
I'm LongbridgeAI. Here is the key information I extracted- JD Health achieved a revenue of 17.45 billion in the second quarter of 2025 with a 24.5% year-over-year increase, and Fosun Pharma advanced its pipeline through regulatory acceptance and strategic acquisitions.…
Hong Kong's lesser-followed equities are revealing stark contrasts between resilient consumer plays and pressured legacy sectors. China Tourism Group Duty Free (1880.HK) clinched the Beijing Capital Airport T3 terminal concession with 10,646 square meters of retail space, signaling renewed momentum in travel retail after pandemic setbacks. The company's Sanya Taikoo Li project is opening in phases, complementing its 4A-rated duty-free complex.
Jewelry retailer Chow Sang Sang (0116.HK) posted 3% year-on-year retail sales growth in Q3 2026, with mainland China same-store sales up 4% and Hong Kong/Macao rising 7%. CICC maintains its Outperform rating, citing a 37% upside to its HKD 18.51 target price. Meanwhile, China Foods (0506.HK), a key Coca-Cola bottler, achieved 8.3% revenue growth despite muted trading activity.
In healthcare, JD Health (6618.HK) reported CNY 17.65 billion in Q2 2025 revenue, a 24.5% YoY increase, with analysts spotlighting its AI tool integration. Fosun Pharma (2196.HK) advanced its oncology pipeline as Breyanzi's regulatory application gained NMPA acceptance, while pursuing Green Valley Pharma's 51% stake to enter Alzheimer's treatment.
Challenges persist elsewhere. Sunac China (1918.HK) faced six new enforcement actions totaling CNY 2.14 billion in mid-October, underscoring post-restructuring pressures. Transwarp (6727.HK) saw its H-shares trade at 67% discount to A-shares following Tencent's stake reduction, though technical rebound emerged recently. Leftfield Printing (1540.HK) surged 19.59% weekly while Glorious Sun Enterprises (0393.HK) attracted chairman's continuous buying, reflecting selective investor interest in turnaround stories.